ALLK Live signals | Maximize Profits with Getagraph.com

SELL 101781 min ago

@ $1.285

Issued: 14 Feb 2024 @ 13:34

Return: -20.62%

Previous signal: Feb 14 - 10:47

Previous signal: Buy

Return: 4.47 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	160 627
Average Volume	785 898
Market Cap	89.63M
EPS	$0 ( 2024-03-18 )
Next earnings date	( $-0.410 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.00500 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Radford Harlan Baird	Sell	32 142	Common Stock
2024-03-05	Tomasi Adam	Sell	47 392	Common Stock
2024-03-04	Alexander Robert	Sell	70 910	Common Stock
2024-02-16	Radford Harlan Baird	Buy	900 000	Stock Option (Right to buy)
2024-02-16	Lee Chin Hyok	Buy	500 000	Stock Option (Right to buy)

INSIDER POWER
57.99
Last 96 transactions
Buy: 11 461 350 \| Sell: 2 630 713

Volume Correlation

Long: 0.00 (neutral)

Short: 0.82 (strong)

Signal:(54.056) Same movement expected

Allakos Inc Correlation

10 Most Positive Correlations
VRAY	0.968
DSKE	0.963
NAKD	0.963
EXFY	0.962
ODT	0.961
CMBM	0.958
ALGT	0.958
BNR	0.958
ALRS	0.956
BZFD	0.956

10 Most Negative Correlations
ALTR	-0.957
NVDA	-0.954
GPACU	-0.952
PESI	-0.95
PRDO	-0.95
NVCN	-0.95
OHAA	-0.95
RAM	-0.948
DSEY	-0.948
SENEA	-0.946

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Allakos Inc Correlation - Currency/Commodity

-0.41
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.01
( neutral )

Allakos Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-6.14M (0.00 %)
EPS:	$-2.14

Q4	2023
Revenue:	$0
Gross Profit:	$-1.55M (0.00 %)
EPS:	$-0.710

Q3	2023
Revenue:	$0
Gross Profit:	$-1.55M (0.00 %)
EPS:	$-0.520

Q2	2023
Revenue:	$0
Gross Profit:	$-1.83M (0.00 %)
EPS:	$-0.410

Financial Reports:

No articles found.

Allakos Inc

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.